RGD Reference Report - Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.

Authors: Brito, Victor Gustavo Balera  Patrocinio, Mariana Sousa  de Sousa, Maria Carolina Linjardi  Barreto, Ayná Emanuelli Alves  Frasnelli, Sabrina Cruz Tfaile  Lara, Vanessa Soares  Santos, Carlos Ferreira  Oliveira, Sandra Helena Penha 
Citation: Brito VGB, etal., Front Pharmacol. 2020 Nov 11;11:579926. doi: 10.3389/fphar.2020.579926. eCollection 2020.
RGD ID: 329956421
Pubmed: PMID:33364953   (View Abstract at PubMed)
PMCID: PMC7751694   (View Article at PubMed Central)
DOI: DOI:10.3389/fphar.2020.579926   (Journal Full-text)

Periodontal disease (PD) is a prevalent inflammatory disease with the most severe consequence being the loss of the alveolar bone and teeth. We therefore aimed to evaluate the effects of telmisartan (TELM), an angiotensin II type 1 receptor (Agtr1) antagonist, on the PD-induced alveolar bone loss, in Wistar (W) and Spontaneous Hypertensive Rats (SHRs). PD was induced by ligating the lower first molars with silk, and 10 mg/kg TELM was concomitantly administered for 15 days. The hemimandibles were subjected to microtomography, ELISA was used for detecting tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), CXCL3, and CCL2, while qRT-PCR was used for analyzing expression of components of renin-angiotensin system (RAS) (Agt, Ace, Agt1r, Agt2r, Ace2, and Masr), and bone markers (Runx2, Osx, Catnb, Alp, Col1a1, Opn, Ocn, Bsp, Bmp2, Trap, Rank, Rankl, CtsK, Mmp-2, Mmp-9, and osteoclast-associated receptor (Oscar)). The SHR + PD group showed greater alveolar bone loss than the W + PD group, what was significantly inhibited by treatment with TELM, especially in the SHR group. Additionally, TELM reduced the production of TNF-α, IL-1β, and CXCL3 in the SHR group. The expression of Agt increased in the groups with PD, while Agtr2 reduced, and TELM reduced the expression of Agtr1 and increased the expression of Agtr2, in W and SHRs. PD did not induce major changes in the expression of bone formation markers, except for the expression of Alp, which decreased in the PD groups. The bone resorption markers expression, Mmp9, Ctsk, and Vtn, was higher in the SHR + PD group, compared to the respective control and W + PD group. However, TELM attenuated these changes and increased the expression of Runx2 and Alp. Our study suggested that TELM has a protective effect on the progression of PD, especially in hypertensive animals, as evaluated by the resorption of the lower alveolar bone. This can be partly explained by the modulation in the expression of Angiotensin II receptors (AT1R and AT2R), reduced production of inflammatory mediators, the reduced expression of resorption markers, and the increased expression of the bone formation markers.



Disease Annotations    
Alveolar Bone Loss  (IEP,ISO)
hypertension  (IEP,ISO)

Gene-Chemical Interaction Annotations    
telmisartan  (EXP,ISO)

Objects Annotated

Genes (Rattus norvegicus)
Ace2  (angiotensin converting enzyme 2)
Acp5  (acid phosphatase 5, tartrate resistant)
Agt  (angiotensinogen)
Agtr1a  (angiotensin II receptor, type 1a)
Agtr2  (angiotensin II receptor, type 2)
Alpl  (alkaline phosphatase, biomineralization associated)
Bmp2  (bone morphogenetic protein 2)
Ctsk  (cathepsin K)
Cxcl3  (C-X-C motif chemokine ligand 3)
Ibsp  (integrin-binding sialoprotein)
Il10  (interleukin 10)
Il1b  (interleukin 1 beta)
Il6  (interleukin 6)
Itgav  (integrin subunit alpha V)
Mas1  (MAS1 proto-oncogene, G protein-coupled receptor)
Mmp2  (matrix metallopeptidase 2)
Mmp9  (matrix metallopeptidase 9)
Oscar  (osteoclast associated Ig-like receptor)
Pparg  (peroxisome proliferator-activated receptor gamma)
Runx2  (RUNX family transcription factor 2)
Spp1  (secreted phosphoprotein 1)
Tnf  (tumor necrosis factor)
Tnfrsf11a  (TNF receptor superfamily member 11A)
Tnfrsf11b  (TNF receptor superfamily member 11B)
Tnfsf11  (TNF superfamily member 11)
Vtn  (vitronectin)

Genes (Mus musculus)
Ace2  (angiotensin converting enzyme 2)
Acp5  (acid phosphatase 5, tartrate resistant)
Agt  (angiotensinogen)
Agtr1a  (angiotensin II receptor, type 1a)
Agtr2  (angiotensin II receptor, type 2)
Alpl  (alkaline phosphatase, liver/bone/kidney)
Bmp2  (bone morphogenetic protein 2)
Ctsk  (cathepsin K)
Cxcl3  (C-X-C motif chemokine ligand 3)
Ibsp  (integrin binding sialoprotein)
Il10  (interleukin 10)
Il1b  (interleukin 1 beta)
Il6  (interleukin 6)
Itgav  (integrin alpha V)
Mas1  (MAS1 oncogene)
Mmp2  (matrix metallopeptidase 2)
Mmp9  (matrix metallopeptidase 9)
Oscar  (osteoclast associated receptor)
Pparg  (peroxisome proliferator activated receptor gamma)
Runx2  (runt related transcription factor 2)
Spp1  (secreted phosphoprotein 1)
Tnf  (tumor necrosis factor)
Tnfrsf11a  (tumor necrosis factor receptor superfamily, member 11a, NFKB activator)
Tnfrsf11b  (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin))
Tnfsf11  (tumor necrosis factor (ligand) superfamily, member 11)
Vtn  (vitronectin)

Genes (Homo sapiens)
ACE2  (angiotensin converting enzyme 2)
ACP5  (acid phosphatase 5, tartrate resistant)
AGT  (angiotensinogen)
AGTR1  (angiotensin II receptor type 1)
AGTR2  (angiotensin II receptor type 2)
ALPL  (alkaline phosphatase, biomineralization associated)
BMP2  (bone morphogenetic protein 2)
CTSK  (cathepsin K)
CXCL1  (C-X-C motif chemokine ligand 1)
IBSP  (integrin binding sialoprotein)
IL10  (interleukin 10)
IL1B  (interleukin 1 beta)
IL6  (interleukin 6)
ITGAV  (integrin subunit alpha V)
MAS1  (MAS1 proto-oncogene, G protein-coupled receptor)
MMP2  (matrix metallopeptidase 2)
MMP9  (matrix metallopeptidase 9)
OSCAR  (osteoclast associated Ig-like receptor)
PPARG  (peroxisome proliferator activated receptor gamma)
RUNX2  (RUNX family transcription factor 2)
SPP1  (secreted phosphoprotein 1)
TNF  (tumor necrosis factor)
TNFRSF11A  (TNF receptor superfamily member 11a)
TNFRSF11B  (TNF receptor superfamily member 11b)
TNFSF11  (TNF superfamily member 11)
VTN  (vitronectin)


Additional Information